Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16596278 | 0.85 | CNR1 (0.48) | KMT2ALMNATSHRMAPTMAPK1 | |
| SCHEMBL6683882 | 0.84 | LMNA (0.67) | LMNAGALR3STAT3NOTUM | |
| SCHEMBL18328448 | 0.83 | KMT2A (0.72) | MEN1KMT2ALMNATSHRKDR | |
| SCHEMBL18328454 | 0.81 | TSHR (0.55) | HSD17B10LMNATSHRMAPTALOX15 | |
| SCHEMBL18328452 | 0.81 | TSHR (0.57) | HSD17B10MEN1KMT2ALMNATSHR | |
| SCHEMBL18328459 | 0.75 | HPGD (0.55) | HSD17B10MEN1KMT2ALMNAKDR | |
| SCHEMBL18328455 | 0.74 | MEN1 (0.53) | HSD17B10MEN1KMT2ALMNATSHR | |
| SCHEMBL18328449 | 0.74 | KCNH2 (0.56) | HSD17B10MEN1KMT2ALMNATSHR | |
| SCHEMBL18328450 | 0.74 | MEN1 (0.56) | HSD17B10MEN1KMT2ALMNATSHR | |
| SCHEMBL16180109 | 0.74 | HSD17B10 (0.70) | HSD17B10MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751851-B2 | Molecules and compositions that inhibit gram negative bacteria and their uses | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160368892-A1 | MOLECULES AND COMPOSITIONS THAT INHIBIT GRAM NEGATIVE BACTERIA AND THEIR USES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368892-A1 | MOLECULES AND COMPOSITIONS THAT INHIBIT GRAM NEGATIVE BACTERIA AND THEIR USES | BLVRB, PGLS, GRHPR | HSD17B10 2151/4885MEN1 4766/4885KMT2A 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.